'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Things couldn't have gone any worse for Bristol-Myers Squibb's Opdivo in the CheckMate 026 lung cancer data presented at ESMO. Without even a trend towards efficacy in patients with high levels of PD-L1 expression, imminent erosion of market share by Merck's Keytruda seems inevitable.

When Bristol-Myers Squibb Co. announced a couple months ago that the CheckMate 026 trial of its PD-1 inhibitor Opdivo (nivolumab) in first-line non-small cell lung cancer had failed, it was a major surprise. The failure in the exploratory analyses presented this weekend at the European Society for Medical Oncology, which could have been BMS's saving grace, were another shock, and have some totally re-forecasting the PD-1 market.

Final data for the CheckMate 026 first-line non-small cell lung cancer study, including exploratory analyses at different levels of PD-L1 expression, were presented during the Presidential Symposium at the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By 

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.